November 23rd 2024
Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Practice Connections™: Optimize the Diagnosis and Treatment of HER2-Positive Colorectal Cancer
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
FDA Grants Pembrolizumab Priority Review for Advanced Gastric Cancer
The FDA has granted a priority review to a supplemental Biologics License Application for pembrolizumab (Keytruda) for the treatment of patients who have undergone at least 2 courses of chemotherapy for recurrent or advanced gastric or gastroesophageal junction adenocarcinoma.
FDA Approves Pembrolizumab for Microsatellite Instability-High and Mismatch Repair Deficient Cancers
May 23rd 2017The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
Future of Immunotherapy in Head and Neck Cancer May Be in Combinations
May 22nd 2017Researchers are hoping to build on the success of the KEYNOTE-012 and CheckMate-141 trials, which led to the approvals of pembrolizumab and nivolumab, respectively, by examining anti–PD-1/PD-L1 agents in the frontline and as a part of combination regimens for patients with head and neck cancer.
Dr. Greten on Promising Immunotherapy Agents in HCC
May 19th 2017Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).
Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer
May 18th 2017Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.
Dr. Black on Combinations with Durvalumab in Bladder Cancer
May 17th 2017Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.
Cleveland Clinic Researchers Explore Epigenetic Combo as Immunotherapy Booster
May 16th 2017An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.
Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer
May 15th 2017Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.